Get the Stockscreener App
2.61
5.67%
0.14
After Hours:
2.72
0.11
+4.21%
Tuhura Biosciences Inc stock is traded at $2.61, with a volume of 599.72K.
It is up +5.67% in the last 24 hours and down -16.35% over the past month.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
See More
Previous Close:
$2.47
Open:
$2.54
24h Volume:
599.72K
Relative Volume:
3.26
Market Cap:
$118.81M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+17.04%
1M Performance:
-16.35%
6M Performance:
-36.50%
1Y Performance:
+0.00%
1-Day Range:
$2.44
$2.77
1-Week Range:
$2.10
$2.77
52-Week Range:
$1.80
$7.20
Tuhura Biosciences Inc Stock (HURA) Company Profile
Name
Tuhura Biosciences Inc
Sector
Industry
Phone
813-875-6600
Address
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
2.61 | 118.81M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-25 | Initiated | H.C. Wainwright | Buy |
| Dec-19-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-05-24 | Initiated | Maxim Group | Buy |
Tuhura Biosciences Inc Stock (HURA) Latest News
TuHURA Biosciences (NASDAQ:HURA) Downgraded by Wall Street Zen to “Sell” - Defense World
TuHURA Biosciences Amid Nasdaq Composite Volatility - Kalkine Media
Millennium Management LLC Invests $138,000 in TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences Approves Executive Salary Increases - TipRanks
TuHURA Biosciences announces executive salary increases - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders - PR Newswire
TuHURA Says FDA Lifts Partial Hold on Skin Cancer Study - marketscreener.com
TuHURA Biosciences stock rises following FDA hold lift By Investing.com - Investing.com Nigeria
TuHURA Biosciences stock rises following FDA hold lift - Investing.com
FDA Removes Partial Clinical Hold On TuHURA Biosciences' Phase 3 Accelerated Approval Trial For IFx-2.0 In Advanced Or Metastatic Merkel Cell Carcinoma - marketscreener.com
FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma - PR Newswire
Squarepoint Ops LLC Invests $223,000 in TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences Secures $12.6M for Strategic Initiatives - TipRanks
TuHURA Biosciences: Promising Oncology Advancements and Strategic Acquisitions Drive Buy Rating - TipRanks
TuHURA Biosciences raises $15.5 million for cancer trials By Investing.com - Investing.com South Africa
TuHURA Biosciences, Inc. announced that it expects to receive $12.19 million in funding - MarketScreener
TuHURA Biosciences raises $15.5 million for cancer trials - Investing.com
Tuhura Biosciences Secures $12.5 Mln In Private Offering - MarketScreener
TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy - The Malaysian Reserve
Northern Trust Corp Makes New Investment in TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting - Quantisnow
TuHURA Biosciences: Encountering Serious Cash Issues And A Long Timeline - Seeking Alpha
Kineta and TuHURA Biosciences Announce Merger Agreement - TipRanks
Q3 EPS Estimate for TuHURA Biosciences Decreased by Analyst - Defense World
FY2027 Earnings Estimate for HURA Issued By Zacks Small Cap - Defense World
HURA: First Quarter 2025 Results - MSN
What is HC Wainwright’s Estimate for HURA FY2025 Earnings? - Defense World
HC Wainwright Reaffirms “Buy” Rating for TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update - Eagle-Tribune
TuHURA Biosciences Reports First Quarter 2025 Financial Results And Provides A Corporate Update - marketscreener.com
TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference - Citizen Tribune
TuHURA Biosciences (HURA) to Release Earnings on Tuesday - Defense World
Kineta Amends Merger Agreement with TuHURA Biosciences - TipRanks
TuHURA Biosciences Amends Merger Agreement with Kineta - TipRanks
TuHURA Biosciences initiates Phase 1b/2a study of IFx-Hu2.0 in carcinoma - TipRanks
TuHURA Biosciences begins trial for metastatic cancer therapy By Investing.com - Investing.com Canada
TuHURA Biosciences begins trial for metastatic cancer therapy - Investing.com
TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP) - PR Newswire
TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - ACCESS Newswire
Geode Capital Management LLC Buys New Holdings in TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences Reports Cancer Immunotherapy Safe, Well Tolerated in Clinical Trial - marketscreener.com
TuHURA Biosciences and Kineta present updated results of cancer candidates - TipRanks
TuHURA And Kineta Present Updated Results From Phase I-II Study Of KVA12123 - Nasdaq
TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Resea - Eastern Progress
Press Release Distribution & PR Platform - ACCESS Newswire
TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference - ACCESS Newswire
TuHURA Biosciences (NASDAQ:HURA) vs. Lakeshore Biopharma (NASDAQ:LSB) Head-To-Head Contrast - Defense World
Is TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts? - Insider Monkey
Tuhura Biosciences Inc Stock (HURA) Financials Data
There is no financial data for Tuhura Biosciences Inc (HURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):